TABLE 3.
Characteristics among pre-LT participants with superior (defined as >1 SD from the cohort mean) versus not superior self-rated health
| Superior n=156 (18%) | Not superior n= 699 (82%) | p | |
|---|---|---|---|
| Self-perceived assessment* | 1 (0-1) | 3 (2–3) | <0.001 |
| Clinician-perceived assessment* | 2 (1-3) | 3 (2–3) | <0.001 |
| Age, y* | 58 (48–63) | 57 (49–63) | 0.10 |
| Women | 53 (34) | 301 (43) | 0.04 |
| Race | <0.001 | ||
| White non-Hispanic | 76 (49) | 438 (63) | |
| White Hispanic | 46 (29) | 191 (27) | |
| Black | 8 (5) | 22 (3) | |
| Asian | 26 (17) | 41 (6) | |
| Other | 0 (0) | 7 (1) | |
| BMI*, kg/m2 | 27.6 (24.5–31.9) | 28.2 (25.0–32.9) | 0.33 |
| Work (yes/no) | 48 (31) | 119 (17) | <0.001 |
| Marital Status (Married) | 89 (67) | 391 (66) | 0.82 |
| Income (<$100,000) | 37 (30) | 144 (25) | 0.27 |
| Modified Charlson Comorbidity Index | 0.04 | ||
| 0 | 86 (63) | 381 (60) | |
| 1 | 33 (24) | 114 (18) | |
| >1 | 18 (13) | 137 (22) | |
| Frailty | 23 (15) | 191 (27) | 0.001 |
| Median Liver Frailty Index* | 3.6 (3.1–4.1) | 3.9 (3.5–4.5) | <0.001 |
| Etiology | <0.001 | ||
| Alcohol | 31 (19.9) | 187 (27) | |
| HCV | 58 (37.2) | 203 (29) | |
| NAFLD | 13 (8.3) | 125 (18) | |
| Autoimmune | 20 (12.8) | 109 (16) | |
| Other | 34 (21.8) | 75 (11) | |
| MELD-Na* | 15 (12–19) | 16 (13–20) | 0.08 |
| Dialysis | 7 (4.5) | 30 (4) | 0.91 |
| HE history | 96 (63) | 476 (70) | 0.09 |
| Ascites history | 0.004 | ||
| None | 51 (34) | 150 (22) | |
| Yes | 76 (50) | 356 (53) | |
| Yes (Refractory) | 25 (16) | 171 (25) |
*
median (IQR).
Abbreviations: HCV, hepatitis C Virus; HE, hepatic encephalopathy; NAFLD, non-alcoholic fatty liver disease.